Initializing
Global Pharmaceutical Leader

Medicine
Beyond Borders

Delivering breakthrough APIs, orphan drugs, and CDMO solutions that lower the cost of life-saving medicine for the world's disease epicenters.

300M+ Annual Doses
40+ Countries
3rd Quinine Globally
Scroll to explore

Pioneering
Pharmaceutical
Innovation

Dr. Ashleys HK Limited is a global pharmaceutical manufacturer dedicated to developing and manufacturing specialized APIs and orphan drugs for the world's most critical health challenges.

Under visionary leadership, the company uses proprietary advanced technologies to significantly reduce manufacturing costs of generic and patented drugs — providing affordable, life-saving medicine to populations in Africa, Asia, and beyond.

As the world's third-largest contract manufacturer of Quinine salts and a market leader in antimalarial APIs, Dr. Ashleys stands at the forefront of global health equity.

0+
Countries Served Worldwide
0M+
Annual Medical Doses
0+
Products in Portfolio
0+
Years of Experience

To provide the world's disease epicenters with millions of prescriptions for NCDs and infectious diseases — transcending policy, politics, and geography.

Building a business model that transcends borders — continual research of profitable technology manufacturing breakthroughs that lower the cost and distribution of drugs globally.

🦟 Malaria 🧬 Oncology 🫁 Tuberculosis 🦠 COVID-19 🦷 Dengue Fever ❤️ Cardiovascular 🧠 Neurological 💊 Orphan Drugs
Our Offerings

Pharmaceutical
Solutions

Three core pillars powering global health outcomes through innovation, quality, and advanced manufacturing technology.

⚗️

Active Pharmaceutical Ingredients

Specialized and complex API manufacturing — the cornerstone of our pharmaceutical operations. World's third-largest contract manufacturer of Quinine salts and market leader in antimalarial APIs.

Antimalarials Oncology APIs Antivirals Antibiotics Hormonal APIs
🔬

Orphan Drugs

Taking a leadership role in the underserved market for rare disease treatments. Through our patented low-cost manufacturing technology, we revitalize critical care for patients with rare conditions globally.

Rare Diseases Critical Care Patented Tech Low-Cost Mfg
🏭

CDMO Services

Contract Development and Manufacturing Organization services — essential for pharmaceutical companies bringing new drugs to market efficiently. End-to-end support from development to full-scale manufacturing.

Contract Manufacturing Drug Development Scale-Up Formulation

Critical Disease
Areas We Serve

🦟
Malaria
Market leader in antimalarial APIs. 263M cases annually — we serve 94% in the African region with the industry's lowest-cost drugs.
🧬
Oncology
Low-cost anti-cancer drug manufacturing. Approved in Malaysia with pending distribution across Southeast Asia. Projected 50% of revenue.
💊
Orphan Drugs
$170-215B market with projections to $500B+ by 2032. Patented low-cost manufacturing for rare, critical-care conditions.
🫁
Tuberculosis
Affordable TB drug supply chains to high-burden nations across Africa and Asia Pacific.
🦠
COVID-19
Pandemic-response APIs and treatments distributed to disease epicenters worldwide at breakthrough cost points.
🩸
HIV / STDs
Antiretroviral APIs and STD treatments supporting global public health programs and NGO distribution networks.
🫀
Cardiovascular
Essential cardiovascular APIs addressing non-communicable diseases in emerging markets with limited healthcare access.
🦟
Dengue Fever
Specialized treatments for dengue management distributed across Southeast Asia, South Asia, and Latin America.

International
Quality Standards

Our manufacturing processes and quality systems meet the highest international pharmaceutical standards.

🏅
WHO GMP
World Health Organization Good Manufacturing Practice certified operations
📋
ISO 9001
International quality management system standard for consistent product quality
🔬
ICH Q7
International harmonized guideline for API Good Manufacturing Practice
🌍
USFDA DMF
Drug Master File submissions supporting US FDA regulatory approvals
Worldwide Reach

Global Presence

Delivering life-saving pharmaceuticals across 40+ countries — from Africa's disease epicenters to Southeast Asia and beyond.

Africa — Primary SE Asia HQ
40+
Countries
94%
Africa Malaria Share
#3
Quinine Globally
SEA
Cancer Drug Approval
Get In Touch
Get In Touch

Contact Us

Headquarters
Unit No 1504, 15th Floor Peninsula Square, 18 Sung On Street, Hung Hom Kowloon Hong Kong Sar
Partnerships
We welcome inquiries from pharmaceutical distributors, NGOs, government health agencies, and strategic investors. Our business model transcends policy and geography.

Send a Message

Our global team responds within 24 hours.